HOPE Trial: Outcomes and Clinical Recommendations
The HOPE trial definitively demonstrated that ramipril 10 mg daily reduces cardiovascular death, myocardial infarction, and stroke by 22% in high-risk patients aged ≥55 years with vascular disease or diabetes plus one additional risk factor, establishing ACE inhibitors as essential therapy for cardiovascular risk reduction beyond blood pressure control alone. 1, 2
Key Trial Results
The HOPE study enrolled 9,297 patients over age 55 with evidence of vascular disease or diabetes mellitus plus at least one other cardiovascular risk factor, followed for a mean of 5.0 years. The trial was stopped 6 months early due to overwhelming benefit 1.
Primary Outcomes - Composite Endpoint Reduction:
- 22% reduction in cardiovascular death, MI, and stroke (P<0.001) 2
- Each individual component showed statistical significance independently 1
Individual Component Reductions:
- Stroke: 33% reduction (95% CI 10-50%, P=0.0074) 1
- Myocardial infarction: 22% reduction (95% CI 6-36%, P<0.01) 1, 3
- Cardiovascular death: 37% reduction (95% CI 21-51%, P=0.0001) 1
- All-cause mortality: 24% reduction (95% CI 8-37%) 4
Additional Benefits:
- Revascularization procedures: 18% reduction (P<0.0005) 3
- Cardiac arrest, heart failure, and worsening angina all significantly reduced 2
- New or worsening angina: 12% reduction (P<0.0014) 3
Critical Finding: Beyond Blood Pressure
The mean blood pressure reduction with ramipril was modest—only 3/2 mm Hg in office measurements 2. However, a crucial HOPE substudy revealed marked reductions in 24-hour ambulatory blood pressure that were missed by office measurements alone 2. Even after adjusting for blood pressure changes, ramipril still reduced the composite primary outcome by 25%, indicating vasculoprotective effects independent of blood pressure lowering 1, 4.
Diabetic Population Benefits (MICRO-HOPE Substudy)
Of the 9,541 total patients, 3,577 (37.5%) had diabetes 1. In this diabetic cohort, ramipril demonstrated even more impressive results 1, 5, 4:
- Combined primary outcome: 25% reduction (95% CI 12-36%, P=0.0004) 1, 4
- Overt nephropathy: 24% reduction (P=0.027) 1, 4
- Reduced need for renal dialysis and laser therapy for diabetic retinopathy 1
- New-onset diabetes: 34% reduction in patients without diabetes at baseline 6, 7
Current Clinical Recommendations Based on HOPE
Class I Recommendations (Must Do):
ACE inhibitors should be prescribed to all patients with coronary artery disease who also have diabetes and/or left ventricular systolic dysfunction (Level of Evidence: A) 1, 8
Class IIa Recommendations (Should Do):
ACE inhibitors are reasonable for patients with CAD or other vascular disease even without heart failure or diabetes (Level of Evidence: B) 1
ACE inhibitors are reasonable for patients recovering from unstable angina/NSTEMI in the absence of LV dysfunction, hypertension, or diabetes (Level of Evidence: A) 8
Specific Patient Populations
High-Risk Patients (HOPE Population):
- Age ≥55 years
- Evidence of vascular disease (prior MI, significant CAD by angiography, stroke, peripheral arterial disease)
- OR diabetes mellitus plus ≥1 additional cardiovascular risk factor
- Ramipril 10 mg daily is the evidence-based dose 1, 2
Diabetic Patients:
Ramipril provides both macrovascular (MI, stroke, cardiovascular death) and microvascular (nephropathy, retinopathy) protection 1, 4. ACE inhibitors should be first-line antihypertensive therapy in diabetics with PAD or vascular disease 9.
Peripheral Arterial Disease:
In PAD patients (ABI ≤0.9), ramipril reduced MI, stroke, or vascular death by 25% 9. ACE inhibitors or angiotensin-receptor blockers should be first-line therapy for PAD patients with hypertension 9.
Important Caveats
Patient Selection:
HOPE excluded patients with:
- Clinical heart failure
- Known low ejection fraction (<0.40)
- Clinical proteinuria 4
These exclusions are critical—the benefits demonstrated apply to high-risk patients without these conditions, as separate trials had already established ACE inhibitor benefits in heart failure populations.
Comparison with Other Trials:
- EUROPA (perindopril): 20% reduction in cardiovascular death/MI/cardiac arrest in lower-risk stable CAD patients 2
- PEACE (trandolapril): No significant benefit in very low-risk CAD patients with preserved LV function receiving intensive modern therapy 2
The key insight: ACE inhibitor benefit is proportional to baseline cardiovascular risk. The absolute benefit decreases in lower-risk populations already receiving optimal medical therapy including revascularization and lipid-lowering agents 2.
Practical Implementation Algorithm
- Identify high-risk patients: Age ≥55 with vascular disease OR diabetes + ≥1 risk factor
- Exclude contraindications: Severe renal dysfunction (creatinine clearance <30 mL/min), hyperkalemia (K+ >5 mEq/L), history of angioedema
- Initiate ramipril: Start low (2.5-5 mg daily), titrate to target dose of 10 mg daily as tolerated
- Monitor: Renal function and potassium within 1-2 weeks of initiation and dose changes
- Continue indefinitely: Benefits persist with long-term use (extended follow-up showed sustained benefit for additional 2.6 years) 6
Common Pitfalls to Avoid
- Don't withhold ACE inhibitors because blood pressure is "normal": HOPE patients had baseline BP averaging 139/79 mm Hg, and benefits occurred despite minimal BP reduction 2
- Don't use inadequate doses: The evidence supports ramipril 10 mg daily—lower doses may not provide equivalent benefit 1
- Don't assume all ACE inhibitors are equivalent at any dose: While class effects likely exist, ramipril 10 mg daily is the specifically validated regimen from HOPE
- Don't forget the diabetic population: This group showed particularly robust benefits including microvascular protection 1, 4